Americafirst Capital Management’s Myriad Genetics MYGN Stock Holding History

Americafirst Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,878	Closed	-$244K	–	231
2016 Q3	$244K	Sell	11,878 -33,338	-74%	-$846K	0.2%	123
2016 Q2	$1.38M	Buy	45,216 +4,080	+10%	+$142K	0.9%	49
2016 Q1	$1.54M	Buy	+41,136	New	+$1.55M	0.96%	40
2015 Q3	–	Sell	-23,587	Closed	-$802K	–	205
2015 Q2	$802K	Sell	23,587 -18,677	-44%	-$635K	0.43%	91
2015 Q1	$1.5M	Buy	+42,264	New	+$1.51M	0.74%	48
2014 Q4	–	Sell	-68,510	Closed	-$2.64B	–	265
2014 Q3	$2.64B	Buy	+68,510	New	+$2.56M	1.3%	13

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Americafirst Capital Management's MYGN Position: Q4 2016 in Review

Americafirst Capital Management sold out of Myriad Genetics (MYGN) in Q4 2016, closing a stake of 11,878 shares — an estimated $244K sold.

Americafirst Capital Management first reported a position in MYGN in Q3 2014 and held it in 6 quarters. The position peaked at $2.64B in Q3 2014. 223 funds tracked by Wall St. Rank hold MYGN as of Q4 2016.

Americafirst Capital Management reported no remaining Myriad Genetics position as of Q4 2016 after selling out during the quarter.
Americafirst Capital Management sold 11,878 Myriad Genetics shares in Q4 2016, an estimated $244K.
Americafirst Capital Management first reported a position in Myriad Genetics in Q3 2014 and held it in 6 quarters.
Americafirst Capital Management's Myriad Genetics position peaked at $2.64B in Q3 2014.
223 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2016.

Based on Americafirst Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.